At present, in the development of neuroprotective drugs, considerable attention has been paid to Glucagon-Like Peptide-1 (GLP-1, HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG) analogs used to treat type 2 diabetes and obesity. This evidence concerns the gene GCG and type 2 diabetes mellitus.